Investigating perlecan/HSPG2 as a potential therapeutic target and biomarker for PC not only holds promise for enhancing radiotherapy effectiveness but also offers a pathway towards mitigating the burden of bone metastases and improving patient outcomes. This evidence concerns the gene HSPG2 and pachyonychia congenita.